Evidence map›Paper›PMID 39148003›Full record

ArticleBreast cancer research and treatment2024

Endocrine therapy initiation among women diagnosed with ductal carcinoma in situ from 2001 to 2018.

Erin J Aiello Bowles, Cody Ramin, Jacqueline B Vo, Heather Spencer Feigelson, Jennifer C Gander, Lene H S Veiga, Clara Bodelon, Rochelle E Curtis, Carolyn Brandt, Amy Berrington de Gonzalez and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Erin J Aiello BowlesKaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, 1730 Minor Ave, Suite 1360, Seattle, WA, 98101, USA. erin.a.bowles@kp.org.ORCID http://orcid.org/0000-0001-6287-7391
Cody RaminCedars-Sinai Medical Center, Los Angeles, CA, USA.
Jacqueline B VoDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Heather Spencer FeigelsonBernard J. Tyson Kaiser Permanente School of Medicine, Pasadena, CA, USA.
Jennifer C GanderCenter for Research and Evaluation, Kaiser Permanente Georgia, Atlanta, GA, USA.
Lene H S VeigaDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Clara BodelonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Rochelle E CurtisDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Carolyn BrandtDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Amy Berrington de GonzalezInstitute of Cancer Research, London, UK.
Gretchen L GierachDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.

Funding

Risk-based Imaging Strategies to Improve Breast Cancer Surveillance OutcomesP01CA154292 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Diana L Miglioretti · 2011 to 2026
$52.9M
Commonly Used Medications and Breast Cancer RecurrenceR01CA120562 · NCI · KAISER FOUNDATION HEALTH PLAN OF WASHINGTON · PI BOUDREAU, DENISE M · 2007 to 2011
$2.1M
Group Health Cancer Research Program Research Specialist AwardR50CA211115 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI BOWLES, ERIN JANELLE AIELLO · 2017 to 2021
$919k
SURVEILLANCE EPIDEMIOLOGY &END RESULTS PROGRAMN01CN067009 · CN · FRED HUTCHINSON CANCER RESEARCH CENTER · PI THOMAS, DAVID B · 1996 to 1997
–
NCI NIH HHS Intramural Research ProgramNCI NIH HHS N01 CN067009NCI NIH HHS N01 PC035142NCI NIH HHS P01 CA154292NCI NIH HHS R01 CA120562NCI NIH HHS R50 CA211115RTI International HHSN 26120090017CUS National Cancer Institute HHSN 261201800469PP0, HHSN 261201700708P, HHSN 261201600711P, 1R01CA1205621, P01CA154292, HHSN 261201700564P, HHSN75N91019P00076, HHSN 5N910200327, HHSN 61201400010I, HHSN261201800043C, N01-CN-67009, N01-PC-35142, R50CA211115
6 · The paper itself

Abstract

purposeTrials demonstrating benefits of tamoxifen for women with ductal carcinoma in situ (DCIS) were published > 20 years ago; yet subsequent uptake of endocrine therapy was low. We estimated endocrine therapy initiation in women with DCIS between 2001 and 2018 in a community setting, reflecting more recent years of diagnosis than previous studies.

methodsThis retrospective cohort included adult females ≥ 20 years diagnosed with first primary DCIS between 2001 and 2018, followed through 2019, and enrolled in one of three U.S. integrated healthcare systems. We collected data on endocrine therapy dispensings (tamoxifen, aromatase inhibitors [AIs]) from electronic pharmacy records within 12 months after DCIS diagnosis. Using generalized linear models with a log link and Poisson distribution, we estimated endocrine therapy initiation rates over time and by patient, tumor (including estrogen receptor [ER] status), and treatment characteristics.

resultsAmong 2020 women with DCIS, 587 (29%) initiated endocrine therapy within 12 months after diagnosis (36% among 1208 women with ER-positive DCIS). Among women who used endocrine therapy, 506 (86%) initiated tamoxifen and 81 (14%) initiated AIs. Age-adjusted endocrine therapy initiation declined from 34 to 21% between 2001 and 2017; between 2015 and 2018, AI use increased from 8 to 35%. Women less likely to initiate endocrine therapy were ER-negative or had borderline/unknown or no ER test results, ≥ 65 years at diagnosis, Black, and received no radiotherapy.

conclusionOne-third of women diagnosed with DCIS initiated endocrine therapy, and use decreased over time. Understanding why women eligible for endocrine therapy do not initiate is important to maximizing disease-free survival following DCIS diagnosis.

Indexed as

Antineoplastic Agents, HormonalAromatase InhibitorsBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingTamoxifenAdultAgedAged, 80 and overFemaleHumansMiddle AgedReceptors, EstrogenRetrospective StudiesAntineoplastic Agents, HormonalAromatase InhibitorsReceptors, EstrogenTamoxifenAromatase inhibitorsBreast cancerDCISEstrogen receptorTamoxifen

Identifiers

PMID39148003
PMCPMC12510238

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.